The European Medicines Agency (EMA) actively engages with patients and consumers.
The Agency is committed to working closely with patients and consumers, as these groups are key stakeholders with specific knowledge, experience and expertise. They contribute a crucial ‘real-life’ perspective to scientific discussions on medicines, which supports better outcomes in the regulatory process. Their involvement in many areas of the Agency's work is now well established.
Key milestones of EMA interactions with patients and consumers
The basis for involving patients and consumers in Agency activities is the EMA framework for interaction with patients and consumer organisations. A revised framework was endorsed by the Management Board in 2014.
- Revised framework on the interaction of the Agency with patients and consumers and their organisations
The levels and types of interactions between the Agency and patients, consumers and their organisations can be seen in the annual reports found under key documents.
Activities of patients and consumers
Patients and consumers are involved in a wide range of activities at the Agency, including:
- as members of the Management Board;
- as members of scientific committees;
- being consulted on disease-specific requests by the scientific committees and working parties;
- taking part in discussions on the development and authorisation of medicines;
- reviewing written information on medicines prepared by the Agency;
- being involved in the preparation of guidelines;
- taking part in the Agency's conferences and workshops.
Overview of patient involvement along the medicines lifecycle at EMA
How useful is this page?
Average rating:Based on 35 ratings
Add your rating:
- See all ratings
22 ratings1 ratings2 ratings4 ratings6 ratings